Aug 1, 2025 · On a per share basis, Endo shareholders are entitled to receive approximately $1.31 in cash and 0.2575 of Mallinckrodt shares. Endo shares have ceased trading on the OTCQX.

Mar 13, 2025 · Mallinckrodt and Endo plan to combine their generic pharmaceuticals businesses and Endo's sterile injectables business after the close of the transaction and intend to separate that …

Mallinckrodt and Endo are merging to create a leading global therapeutics company with branded and generic products. Stay tuned for updates.

As announced on March 13, 2025, the proposed Mallinckrodt and Endo transaction envisions the spin-off of the combined generic pharmaceuticals businesses and Endo's sterile injectables business into …

Oct 9, 2025 · Mallinckrodt and Endo have merged to create a global, scaled, diversified therapeutics leader. Visit our new Investor Relations website at ir.mallinckrodt.com for up-to-date investor …

Jun 9, 2025 · Mallinckrodt and Endo commenced mailing of the definitive joint proxy statement/prospectus to shareholders of Mallinckrodt and Endo, respectively, on or about May 12, …

Oct 20, 2025 · The generic formulation offers a new option for both adult and pediatric patients managing rare metabolic conditions. This launch represents a key first-to-market generic entry for …

Sep 23, 2025 · Endo, a wholly owned subsidiary of Mallinckrodt plc, is a diversified therapeutics manufacturer boldly transforming insights into life-enhancing therapies. Our passionate team …

Mar 13, 2025 · Endo is providing the following financial guidance for the full year ending December 31, 2025 based on Endo's current views, beliefs, estimates and assumptions.

Aug 1, 2025 · Endo, Inc. ("Endo"), a newly formed entity, today announced that its wholly-owned subsidiary Endo Finance Holdings, Inc. (the "Borrower") intends to enter into new senior secured …